New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
08:17 EDTMRTXMirati Therapeutics price target raised to $27 from $20 at Brean Capital
Brean Capital raised its price target on Mirati Therapeutics as the company continues to move its pipeline forward, positive trials updates, and expectations for upfront payments and royalties from potential partnerships. Shares are Buy rated.
News For MRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 23, 2015
14:38 EDTMRTXMirati Therapeutics to present data on MGCD265, MGCD516 cancer drugs
Mirati Therapeutics announced it will present data on its two tyrosine kinase inhibitors, MGCD265 and MGCD516, at the International Association of Lung Cancer 16th World Conference on Lung Cancer being held September 6-9. The titles of the two oral presentations are "Evaluation of the MET/Axl Receptor Tyrosine Kinase Inhibitor MGCD265 in a Patient with Metastatic Non-Small Cell Lung Cancer Harboring Axl Amplification" and "In Vitro and In Vivo Evaluation of the Kinase Inhibitor, MGCD516, in Trk and RET Fusion Cancer Cells."

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use